Aduro BioTech (NASDAQ:ADRO) has been assigned a $8.00 target price by investment analysts at HC Wainwright in a report issued on Monday, November 12th. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 211.28% from the company’s current price.
Several other equities analysts have also recently issued reports on ADRO. ValuEngine cut Aduro BioTech from a “sell” rating to a “strong sell” rating in a research report on Tuesday, July 24th. BidaskClub cut Aduro BioTech from a “hold” rating to a “sell” rating in a research report on Wednesday, July 25th. Bank of America lowered their price objective on Aduro BioTech from $8.00 to $6.00 and set an “underperform” rating on the stock in a research report on Thursday, August 2nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Aduro BioTech in a research report on Thursday, August 2nd. Finally, William Blair reaffirmed a “buy” rating on shares of Aduro BioTech in a research report on Wednesday, October 3rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. Aduro BioTech has an average rating of “Buy” and a consensus target price of $8.63.
Shares of ADRO traded up $0.07 during mid-day trading on Monday, reaching $2.57. The company had a trading volume of 1,655,730 shares, compared to its average volume of 869,992. Aduro BioTech has a 52 week low of $2.47 and a 52 week high of $9.93. The stock has a market cap of $196.92 million, a P/E ratio of -1.81 and a beta of 2.57.
Aduro BioTech (NASDAQ:ADRO) last issued its quarterly earnings results on Tuesday, October 30th. The biotechnology company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.02. The firm had revenue of $3.06 million for the quarter, compared to analysts’ expectations of $4.59 million. Aduro BioTech had a negative return on equity of 50.03% and a negative net margin of 591.66%. As a group, sell-side analysts forecast that Aduro BioTech will post -1.18 EPS for the current fiscal year.
In other Aduro BioTech news, insider Stephen T. Isaacs sold 62,572 shares of the business’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $7.91, for a total transaction of $494,944.52. Following the completion of the sale, the insider now directly owns 221,331 shares in the company, valued at approximately $1,750,728.21. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Blaine Templeman sold 6,056 shares of the company’s stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $6.50, for a total value of $39,364.00. Following the completion of the sale, the vice president now owns 147,437 shares of the company’s stock, valued at $958,340.50. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 109,499 shares of company stock valued at $789,863. Company insiders own 5.00% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Aduro BioTech by 9.9% during the third quarter. Vanguard Group Inc. now owns 4,029,445 shares of the biotechnology company’s stock worth $29,617,000 after buying an additional 362,516 shares during the period. MetLife Investment Advisors LLC increased its holdings in Aduro BioTech by 55.2% in the third quarter. MetLife Investment Advisors LLC now owns 49,337 shares of the biotechnology company’s stock valued at $363,000 after buying an additional 17,538 shares in the last quarter. Aquilo Capital Management LLC increased its stake in shares of Aduro BioTech by 4.8% during the third quarter. Aquilo Capital Management LLC now owns 2,105,282 shares of the biotechnology company’s stock worth $15,474,000 after purchasing an additional 97,383 shares in the last quarter. Jefferies Group LLC increased its stake in shares of Aduro BioTech by 263.5% during the third quarter. Jefferies Group LLC now owns 46,532 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 33,732 shares in the last quarter. Finally, Baillie Gifford & Co. increased its stake in shares of Aduro BioTech by 9.5% during the third quarter. Baillie Gifford & Co. now owns 3,076,825 shares of the biotechnology company’s stock worth $22,615,000 after purchasing an additional 266,317 shares in the last quarter. Hedge funds and other institutional investors own 48.32% of the company’s stock.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Featured Article: Earnings Per Share